Skip to main content
SpringerLink
Log in

Nintedanib plus Pirfenidon bei Idiopathischer Lungenfibrose

Akzeptables Sicherheits- und Verträglichkeitsprofil

  • journal club
  • Published:
Pneumo News Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183:788–824.

    Article  PubMed  Google Scholar 

  2. Park JH1, Kim DK, Kim DS, et al. Mortality and risk factors for surgical lung biopsy in patients with idiopathic interstitial pneumonia, Eur J Cardiothorac Surg. 2007;31(6):1115–9.

    Article  PubMed  Google Scholar 

  3. Casoni GL, Tomassetti S, Cavazza A et al. Transbronchial lung cryobiopsy in the diagnosis of fibrotic interstitial lung diseases., PLoS One. 2014;28;9(2):e86716. doi: 10.1371/journal.pone.0086716. eCollection 2014.

    Article  Google Scholar 

  4. Raghu G1, Lynch D2, Godwin JD3, et al. Diagnosis of idiopathic pulmonary fibrosis with high-resolution CT in patients with little or no radiological evidence of honeycombing: secondary analysis of a randomised, controlled trial. Lancet Respir Med. 2014;2(4):277–84. doi: 10.1016/S2213-2600(14)70011-6. Epub 2014 Feb 18.

    Article  PubMed  Google Scholar 

  5. Martinez FJ, Liu LX, Murray S,et al. Clinical predictors of a diagnosis of idiopathic pulmonary fibrosis. Fell CD1. Am J Respir Crit Care Med. 2010;181(8):832–7. doi: 10.1164/rccm.200906-0959OC. Epub 2010 Jan 7.

    Article  PubMed Central  PubMed  Google Scholar 

Literatur

  • Ogura T, Taniguchi H, Azuma A et al. Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 2015; 45(5):1382–92.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medizinische Klinik V, Pneumologie Herz-Thorax-Zentrum Fulda, Klinikum Fulda gAG, Pacelliallee 4, 36043, Fulda, Deutschland

    Philipp Markart (Direktor)

  2. Stellvertretender Leiter Schwerpunkt: „Fibrosierende Lungenerkrankungen“, Universitätsklinikum Giessen Marburg GmbH, Klinikstrasse 36, 35392, Giessen, Deutschland

    Philipp Markart (Direktor) &  Andreas Günther (Chefarzt)

  3. AGAPLESION Pneumologische Klinik, Waldhof-Elgershausen, 35753, Greifenstein, Deutschland

    Andreas Günther (Chefarzt)

Authors
  1. Philipp Markart
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andreas Günther
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Philipp Markart.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Markart, P., Günther, A. Akzeptables Sicherheits- und Verträglichkeitsprofil. Pneumo News 7, 21–22 (2015). https://doi.org/10.1007/s15033-015-0137-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15033-015-0137-4

Search

Navigation